Hostility Conflict and Reporting of Side Effects by Psychiatric Outpatients

1980 ◽  
Vol 47 (1) ◽  
pp. 319-324 ◽  
Author(s):  
Robert W. Downing ◽  
Karl Rickels
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Self Report ◽  
Partial Replication ◽  
Drug Trials ◽  
Psychiatric Outpatients ◽  
Double Blind ◽  
The Relationship ◽  
Report Measure

The Irritability, Indirect Hostility, Verbal Hostility, and Resentment scales from the Buss-Durkee Hostility Inventory, along with a newly constructed scale intended as a self-report measure of Hostility Conflict, were administered to 84 non-psychotic, primarily anxious psychiatric outpatients receiving an active anxiolytic and participating in one of several 4-wk. double-blind drug trials. Patients who complained of one or more side effects after 2 wk. of treatment were classified as side reactors; the remaining patients, as non-side reactors. Compared to non-side reactors, the side reactors obtained higher hostility conflict scores and lower scores on the Irritability and Indirect Hostility scales. Also, the relationship between side effect status and hostility conflict was stronger in those patients who obtained higher scores on the Irritability, Indirect Hostility, and Verbal Hostility scales and among patients obtaining lower scores on the Resentment scale. Findings were regarded as providing partial replication of and further verification of earlier results.

The Initiation of Long-Term Pharmacotherapy in Schizophrenia: Dosage and Side Effect Comparisons Between Oral and Depot Fluphenazine*

1976 ◽  
Vol 09 (04) ◽  
pp. 159-169 ◽  
Author(s):  
Nina R. Schooler ◽  
J. Levine ◽  
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Dosage Forms ◽  
The Other ◽  
Oral Drug ◽  
Double Blind ◽  
Moderate Severity ◽  
Treatment Groups ◽  
The Relationship

SummaryThis report focuses on two comparisons between oral and depot fluphenazine specifically FPZ decanoate: 1) can equivalent dosages for the two drugs be established and do these equivalencies change over six months of treatment; 2) what are the side effects seen with the two drugs during the early weeks of administration.Patients in the study receive either oral or depot FPZ as the active treatment but in order to preserve double blind conditions, they are also given the other treatment in placebo form. No dosage equivalence is established by the protocol, however, if dosage is adjusted, both forms must be changed and in the same direction. During the first weeks of treatment there is a linear relationship between the two dosage forms but a range of relatively low dosages of the oral compound (5-20 mg) is associated with a single dose (25 mg/q 3 weeks) of FPZ decanoate. At higher dosages of the oral drug the relationship is linear. Side effects of some kind are noted in over 60 percent of patients in both treatment groups after four weeks of treatment, while symptoms of at least moderate severity occur in almost 40 percent. Only symptoms involving the extrapyramidal system and sleep disturbance are observed in more than 20 percent of the patients. Benztropine was prescribed only if needed and was administered to 65 percent of patients. In general, those receiving benztropine had more side effects than those who did not. These differences reached significance for extrapyramidal symptoms and depression.Based on these data, we conclude that at the dosages used in this study there are no side effect differences between these two forms of fluphenazine in the early weeks of administration. Dosage equivalence between the two drugs can be set within the range of 5- 60 mg/day oral and 12.5-100 mg/three weeks depot.

scholarly journals Let Others Buy First: Identity Fusion Buffers the Effect of COVID-19 Phobia on Panic Buying Behavior From an Economic Perspective

2021 ◽  
Vol 12 ◽  
Author(s):  
Yi-Tai Seih ◽  
Vi Thanh Tra ◽  
Marketa Lepicovsky ◽  
Yi-Ying Chang
Keyword(s):  
Economic Factor ◽  
The United States ◽  
Self Report ◽  
Economic Perspective ◽  
Buying Behavior ◽  
Identity Fusion ◽  
Control And Prevention ◽  
Fusion Theory ◽  
The Relationship ◽  
Report Measure

The coronavirus 2019 (COVID-19) pandemic has caused hundreds of millions of cases and millions of deaths, resulting in the development of COVID-19 phobia. To prevent getting COVID-19, Centers for Disease Control and Prevention (CDC) in many countries encourage people to protect themselves via several strategies, such as wearing face masks or using sanitizers when washing hands. However, at times, such supplies for preventing COVID-19 are limited. In this study, we examine the relationship between COVID-19 phobia and panic buying behavior from an economic perspective and test if identity fusion plays a buffering role for this phenomenon. Data was collected from September 4th to November 1st in 2020 across three countries (the United States, Germany, and Taiwan). A self-report measure of panic buying behavior was developed and culturally cross-validated. Moderation analyses were conducted focusing on the study objectives. Results show that the economic factor in COVID-19 phobia predicts panic buying behavior, and this effect is buffered by identity fusion. It is worthy to note that this buffering effect emerged only in the Taiwanese sample, not in the American or German samples. Implications of identity fusion theory in human behavior are discussed.

scholarly journals The association between body dysmorphic symptoms and suicidality among adolescents and young adults: a genetically informative study

2020 ◽  
pp. 1-9
Author(s):  
Georgina Krebs ◽  
Lorena Fernández de la Cruz ◽  
Frühling V. Rijsdijk ◽  
Daniel Rautio ◽  
Jesper Enander ◽  
...  
Keyword(s):  
Suicidal Ideation ◽  
Regression Models ◽  
Genetic Factors ◽  
Body Dysmorphic Disorder ◽  
Early Adulthood ◽  
Self Report ◽  
Logistic Regression Models ◽  
Substantial Risk ◽  
The Relationship ◽  
Report Measure

Abstract Background Previous research indicates that body dysmorphic disorder (BDD) is associated with risk of suicidality. However, studies have relied on small and/or specialist samples and largely focussed on adults, despite these difficulties commonly emerging in youth. Furthermore, the aetiology of the relationship remains unknown. Methods Two independent twin samples were identified through the Child and Adolescent Twin Study in Sweden, at ages 18 (N = 6027) and 24 (N = 3454). Participants completed a self-report measure of BDD symptom severity. Young people and parents completed items assessing suicidal ideation/behaviours. Logistic regression models tested the association of suicidality outcomes with: (a) probable BDD, classified using an empirically derived cut-off; and (b) continuous scores of BDD symptoms. Bivariate genetic models examined the aetiology of the association between BDD symptoms and suicidality at both ages. Results Suicidal ideation and behaviours were common among those with probable BDD at both ages. BDD symptoms, measured continuously, were linked with all aspects of suicidality, and associations generally remained significant after adjusting for depressive and anxiety symptoms. Genetic factors accounted for most of the covariance between BDD symptoms and suicidality (72.9 and 77.7% at ages 18 and 24, respectively), but with significant non-shared environmental influences (27.1 and 22.3% at ages 18 and 24, respectively). Conclusions BDD symptoms are associated with a substantial risk of suicidal ideation and behaviours in late adolescence and early adulthood. This relationship is largely explained by common genetic liability, but non-shared environmental effects are also significant and could provide opportunities for prevention among those at high-risk.

Felt Arousal, Thoughts/Feelings, and Ski Performance

1994 ◽  
Vol 8 (4) ◽  
pp. 360-375 ◽  
Author(s):  
Thomas D. Raedeke ◽  
Gary L. Stein
Keyword(s):  
Significant Relationship ◽  
Poor Performance ◽  
Arousal Level ◽  
Self Report ◽  
Performance Ratings ◽  
The Relationship ◽  
Report Measure ◽  
Ski Racers

This study examined the relationship between felt arousal, thoughts/feelings, and ski performance based on recent arousal and affect conceptualizations. An eclectic integration of these perspectives suggests that to understand the arousal-performance relationship, researchers need to examine not only a felt arousal continuum (i.e., intensity or level ranging from low to high), but also a concomitant thoughts and feelings continuum (i.e., ranging from positive to negative). Recreational slalom ski racers completed a self-report measure examining felt arousal and thoughts/feelings prior to several ski runs. Results demonstrated a significant relationship between felt arousal level, thoughts/feelings, and subjective ski performance ratings, but not for actual ski times. In contrast to the inverted-U hypothesis for subjective performance ratings, high felt arousal is not associated with poor performance ratings if it is accompanied by positive thoughts and feelings.

A Multicentre Double Blind Trial of Fluoxetine versus Amitriptyline in the Treatment of Depressive Illness

1993 ◽  
Vol 27 (1) ◽  
pp. 49-55 ◽  
Author(s):  
Fiona K. Judd ◽  
Kate Moore ◽  
Trevor R. Norman ◽  
Graham D. Burrows ◽  
Ramesh K. Gupta ◽  
...  
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Serotonin Reuptake ◽  
Depressive Illness ◽  
Fixed Dose ◽  
Side Effect Profile ◽  
Double Blind Trial ◽  
Double Blind ◽  
Antidepressant Efficacy ◽  
To Receive

The antidepressant efficacy and side effect profile of a fixed dose of 20 mg/day of fluoxetine, a specific serotonin reuptake inhibitor, were compared to those of amitriptyline. Fifty-eight patients with DSM-III-R depression were randomly assigned to receive either fluoxetine or amitriptyline. Fifty-six patients (fluoxetine N = 23, amitriptyline N = 23) completed the 6 week study. Comparable antidepressant efficacy was demonstrated for the two drugs. Patients taking fluoxetine reported less side-effects than those taking amitriptyline.

Executive Functioning Outcomes Over 6 Months of Atomoxetine for Adults With ADHD: Relationship to Maintenance of Response and Relapse Over the Subsequent 6 Months After Treatment

2016 ◽  
Vol 24 (3) ◽  
pp. 363-372 ◽  
Author(s):  
Lenard A. Adler ◽  
Mary Solanto ◽  
Rodrigo Escobar ◽  
Sarah Lipsius ◽  
Himanshu Upadhyaya
Keyword(s):  
Executive Functioning ◽  
Adult Adhd ◽  
Rating Scale ◽  
Self Report ◽  
Symptom Improvement ◽  
Double Blind ◽  
Behavior Rating Inventory ◽  
The Relationship ◽  
Controlled Clinical Study

Objective: This study examines the relationship between maintenance of improved executive functioning (EF) in adults with ADHD with long-term symptom improvement with atomoxetine. Method: Data were collected from a yearlong, double-blind, placebo-controlled clinical study on adult patients with ADHD receiving atomoxetine (80-100 mg/day) for 24 weeks. Patients were then randomized to continue atomoxetine or placebo for 6 months. Executive functioning was rated with Behavior Rating Inventory of Executive Function–Adult Version: Self-Report™ (BRIEF-A: Self-Report™), and the T-scores were determined. Results: Postrandomization T-scores for atomoxetine patients were significantly better than those of placebo patients (3 and 6 months postrandomization). Patients with greater improvements in EF were more likely to show worsening of EF and to relapse after atomoxetine discontinuation. The maintenance of improved EF was significantly associated with improved ADHD symptoms (Conners’ Adult ADHD Rating Scale–Investigator Rated: Screening Version [CAARS-Inv:SV] with adult prompts). Conclusion: Treatment with atomoxetine improved EF during the treatment phases. Improved EF was maintained up to 6 months after discontinuation of atomoxetine.

scholarly journals What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication

2017 ◽  
Vol 47 (13) ◽  
pp. 2369-2378 ◽  
Author(s):  
T. Wykes ◽  
J. Evans ◽  
C. Paton ◽  
T. R. E. Barnes ◽  
D. Taylor ◽  
...  
Keyword(s):  
Side Effects ◽  
Antipsychotic Medication ◽  
Side Effect ◽  
Self Report ◽  
Psychotic Symptoms ◽  
Service Users ◽  
Good Reliability ◽  
Starting Point ◽  
Two Samples ◽  
Life Impact

BackgroundCapturing service users’ perspectives can highlight additional and different concerns to those of clinicians, but there are no up to date, self-report psychometrically sound measures of side effects of antipsychotic medications.AimTo develop a psychometrically sound measure to identify antipsychotic side effects important to service users, the Maudsley Side Effects (MSE) measure.MethodAn initial item bank was subjected to a Delphi exercise (n = 9) with psychiatrists and pharmacists, followed by service user focus groups and expert panels (n = 15) to determine item relevance and language. Feasibility and comprehensive psychometric properties were established in two samples (N43 and N50). We investigated whether we could predict the three most important side effects for individuals from their frequency, severity and life impact.ResultsMSE is a 53-item measure with good reliability and validity. Poorer mental and physical health, but not psychotic symptoms, was related to side-effect burden. Seventy-nine percent of items were chosen as one of the three most important effects. Severity, impact and distress only predicted ‘putting on weight’ which was more distressing, more severe and had more life impact in those for whom it was most important.ConclusionsMSE is a self-report questionnaire that identifies reliably the side-effect burden as experienced by patients. Identifying key side effects important to patients can act as a starting point for joint decision making on the type and the dose of medication.

Autonomous Sensory Meridian Response

2020 ◽  
pp. 1-8
Author(s):  
Natalie Roberts ◽  
Alissa Beath ◽  
Simon Boag
Keyword(s):  
Sensory Processing ◽  
Self Report ◽  
Survey Study ◽  
Personality Factors ◽  
Big Five Personality ◽  
Confirmatory Factor ◽  
Tingling Sensation ◽  
Big Five Personality Factors ◽  
The Relationship ◽  
Report Measure

Abstract. Autonomous Sensory Meridian Response (ASMR) is a pleasurable, tingling sensation induced by exposure to specific, audio-visual triggers, producing feelings of relaxation and euphoria. This article examines the relationship between ASMR propensity using a recently developed self-report measure (ASMR-15), Big-Five personality factors, and sensory-processing sensitivity (SPS), in a general population. Thus far, the ASMR-15 has only been validated on self-selected ASMR-specific samples, and so it is yet to be determined whether the measure may be adapted to assess ASMR in a non-specialized sample. To address this, N = 187 undergraduate psychology students were recruited for a survey study. ASMR was related to greater Openness and SPS, and lower Conscientiousness. A confirmatory factor analysis was undertaken on the ASMR-15, largely replicating the factor structure previously demonstrated. As a result, the ASMR-15 may be useful for researchers interested in further exploring ASMR experiences in both specialized and non-specialized samples.

Clinical validation of the self-reported Glasgow Antipsychotic Side-effect Scale using the clinician-rated UKU side-effect scale as gold standard reference

2020 ◽  
Vol 34 (8) ◽  
pp. 820-828
Author(s):  
Marlene Schouby Bock ◽  
Oona Nørgaard Van Achter ◽  
David Dines ◽  
Maria Simonsen Speed ◽  
Christoph U Correll ◽  
...  
Keyword(s):  
Side Effects ◽  
Positive Predictive Value ◽  
Negative Predictive Value ◽  
Predictive Value ◽  
Gold Standard ◽  
Side Effect ◽  
Self Report ◽  
Measurement Based Care ◽  
Gold Standard Reference ◽  
Antipsychotic Side Effects

Background: Antipsychotics are key for the treatment of psychotic and several non-psychotic disorders. Unfortunately, antipsychotic medications are associated with side effects, which may reduce quality of life and treatment adherence. Therefore, regular screening of antipsychotic side effects is essential. The Glasgow Antipsychotic Side-effect Scale is a patient self-report scale developed for this purpose. However, the Glasgow Antipsychotic Side-effect Scale has only been validated against another self-report side effect measure, which is suboptimal. Objective: We aimed to validate the Glasgow Antipsychotic Side-effect Scale using the clinician-rated Udvalg for Kliniske Undersøgelser side-effect rating scale as the gold standard reference. Results: 81 antipsychotic-treated outpatients with schizophrenia-spectrum disorders (age = 42±13 years; males = 43%, schizophrenia = 77%, illness duration: median = 11 years) completed the Glasgow Antipsychotic Side-effect Scale and were subsequently scored on the Udvalg for Kliniske Undersøgelser by trained raters. Sensitivity, specificity, positive predictive value and negative predictive value were calculated for paired Glasgow Antipsychotic Side-effect Scale and Udvalg for Kliniske Undersøgelser items. Sensitivity of Glasgow Antipsychotic Side-effect Scale items ranged from 33–96%, with 19 (86%) having >75% sensitivity. Lowest sensitivity emerged for “nocturnal enuresis” (33%), “galactorrhea” (50%) and “hyperkinesia” 14–99%, with 14 items (64%) having >75% specificity, being lowest for “asthenia” (14%), “polyuria/polydipsia” (35%), “sedation” (41%), “akathisia” (53%), “dystonia” (65%), “hyperkinesia” (68%), “hypokinesia” (70%) and “accommodation” (70%). Positive predictive value ranged from 7–85%, with six items (27%) having a positive predictive value >75%. Negative predictive value ranged from 40–98%, with 21 items (95%) having a negative predictive value >75%. The mean time to complete the Glasgow Antipsychotic Side-effect Scale was 4±2 minutes. Conclusion: The Glasgow Antipsychotic Side-effect Scale demonstrated satisfactory validity as a self-rated tool for antipsychotic side effects and may aid measurement-based care and decision-making.

Sign in / Sign up

Export Citation Format

Share Document